human bace1

BACE1-IN-1 is a high brain penetrant BACE1 inhibitor (IC50s: 32 and 47 nM for human BACE1 and BACE2).

Umibecestat is an inhibitor of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), with IC50s of 11 nM and 10 nM for human BACE-1 and mouse BACE-1, respectively. Umibecestat can be used for the research of alzheimer's disease.

NB-360 is a potent and brain-penetrable inhibitor of BACE1 and BACE2 with IC50s of 5, 5, and 6 nM for mouse and human BACE1 and BACE2. NB-360 exhibits excellent selectivity over the related aspartyl proteases pepsin, cathepsin E, and cathepsin D.

hAChE/hBACE-1-IN-1 (compounds 5d) is an orally active inhibitor of hAChE that can cross the blood-brain barrier. It effectively inhibits hAChE and hBACE-1, with IC50 values of 0.076 and 0.23 μM, respectively. Additionally, hAChE/hBACE-1-IN-1 prevents Aβ1-42 aggregation and enhances learning and memory in mice. This compound is useful in Alzheimer's disease research.

Memoquin is a multi-target-directed ligand for the therapy of Alzheimer's disease.

Potent and selective β-secretase (BACE) inhibitor (IC50 values are 10.2 and 20.3 nM for human BACE2 and BACE1, respectively). Displays >5,000-fold selectivity for BACE over other proteases including cathepsin D, pepsin and renin. Inhibits Aβ1-40 and Aβ1-42 production in cells expressing mutated APP. Reduces hippocampal and cortical Aβ and sAPPβ levels in an Alzheimer's disease mouse model.

OM99-2 TFA is an eight-residue peptidomimetic compound, functioning as a tight-binding inhibitor of human brain memapsin 2. It exhibits a high affinity for the target with a Ki value of 9.58 nM, making it a promising candidate in the development of BACE1 inhibitors. Due to its potential, OM99-2 presents opportunities for further research in the field of Alzheimer's disease.

OM99-2 is an eight-residue peptidomimetic with a high affinity for human brain memapsin 2, exhibiting a Ki value of 9.58 nM. This compound represents a significant advancement in the development of BACE1 inhibitors and holds potential for the study of Alzheimer's disease.

PD07 is an orally active acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 of 0.29 μM against human AChE, and demonstrates inhibition of cholinesterases (ChEs), β-site amyloid precursor protein cleaving enzyme 1 (BACE1) with an IC50 of 13.42 μM, as well as Aβ1–42 aggregation in vitro. Additionally, PD07 possesses antioxidant properties with a DPPH radical inhibition IC50 value of 26.46 μM and has been shown to ameliorate memory and cognitive deficits in scopolamine-induced amnesic rats. This compound is relevant for Alzheimer's disease research [1].

BuChE-IN-8 (compound 19c), a butyrylcholinesterase (BuChE) inhibitor, exhibits an IC50 value of 559 nM and concurrently inhibits human β-secretase (BACE1) and Aβ40 aggregation. It also demonstrates notable antiamnesic properties [1].

BuChE-IN-9 (compound 22a), an eqBuChE (equine serum-derived butyrylcholinesterase) inhibitor, exhibits potent activity with an IC50 of 173 nM. In addition to eqBuChE, it also inhibits human BACE1, Aβ aggregation, and mouse GABA transporters 1 and 4 (mGAT1 and mGAT4). Notably, BuChE-IN-9 demonstrates significant antiamnesic properties [1].

Anti-BACE1 Antibody is a human-derived antibody expressed in CHO cells, targeting BACE1. The predicted molecular weight (MW) of Anti-BACE1 Antibody is 145 kDa. For its isotype control, refer to HumanIgG1kappa, Isotype Control.